The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response

Objective To assess the efficacy of erenumab at the ≥50%, ≥75%, and 100% reduction in monthly migraine days (MMD) response thresholds, using data from the 6‐month double‐blind treatment phase (DBTP) of the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention (STRIVE) pivotal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Headache 2020-10, Vol.60 (9), p.2026-2040
Hauptverfasser: Broessner, Gregor, Reuter, Uwe, Bonner, Jo H., Dodick, David W., Hallström, Yngve, Picard, Hernan, Zhang, Feng, Lenz, Robert A., Klatt, Jan, Mikol, Daniel D.
Format: Artikel
Sprache:eng
Schlagworte:
Clinical Neurology
Clinical trials
Double-blind studies
efficacy
episodic migraine
erenumab
Headache
Health services
Life Sciences & Biomedicine
Migraine
Monoclonal antibodies
Neurosciences & Neurology
Patients
Reduction
Research Submissions
responder thresholds
Science & Technology
STRIVE double‐blind treatment phase
Subgroups
Thresholds
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To assess the efficacy of erenumab at the ≥50%, ≥75%, and 100% reduction in monthly migraine days (MMD) response thresholds, using data from the 6‐month double‐blind treatment phase (DBTP) of the Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention (STRIVE) pivotal clinical trial. Methods Enrolled patients with episodic migraine (EM; ≥4 MMD and
ISSN:0017-8748
1526-4610
DOI:10.1111/head.13929